Startseite Medizin Risk and prognosis for brain metastasis in primary metastatic cervical cancer patients: A population-based study
Artikel Open Access

Risk and prognosis for brain metastasis in primary metastatic cervical cancer patients: A population-based study

  • Jiao Wu , Qing Xu , Huixia Huang , Yangyang Pang , Haoran Li EMAIL logo und Xi Cheng EMAIL logo
Veröffentlicht/Copyright: 22. August 2025

Abstract

Purpose

The purpose of this study was to evaluate the risk and prognostic factors of stage IVB cervical cancer with brain metastasis from a population-based database, the Surveillance, Epidemiology and End Results (SEER).

Patients and methods

Cervical cancer patients initially diagnosed with brain metastasis between 2010 and 2019 were included in this study. The risk factors of developing brain metastasis were evaluated by logistic regression model with corresponding 95% confidence interval (95% CI). Survival analysis was performed through the Kaplan–Meier method, log-rank test, and Cox proportional hazards model.

Results

A total of 88 (88/25,476, 0.35%) cervical cancer patients initially diagnosed with brain metastasis between 2010 and 2019 were retrieved. Accompanied with lung, bone, or liver metastasis (all P < 0.001) was shown to be independent risk factors for developing brain metastasis. Patients with brain metastasis indicated a poor prognosis (P < 0.001, hazards ratio [HR] = 2.84, 95% CI = 1.71–4.72) with a 2.84-fold elevated risk of death compared with patients without brain metastasis. The median survival month for patients with brain metastasis was 6 months, which is much shorter compared with the lung (9 months) or liver (8.5 months) or bone (11 months) metastasis group. Along with lower tumor grade (P = 0.001, HR = 0.27, 95% CI = 0.09–0.76) and with bone metastasis (P = 0.007, HR = 2.74, 95% CI = 1.33–5.67) demonstrated poor overall survival outcomes in patients with brain metastasis, with a 3.7- and 1.33-fold higher risk of death, respectively. In terms of treatment modality, chemoradiotherapy tended to prolong the survival of stage IVB cervical cancer patients with brain metastasis (P = 0.001, HR = 0.17, 95% CI = 0.06–0.48), with an 83% reduction in the risk of death.

Conclusion

In conclusion, the prognosis of stage IVB cervical cancer patients with brain metastasis remains poor. Chemoradiotherapy may provide survival benefits, which deserves large-scale prospective clinical trials to confirm.

1 Introduction

Cervical cancer ranked as fourth most prevalent and fourth leading lethal malignancy in women worldwide, with nearly 604,000 new cases and 342,000 deaths in 2020 [1,2]. According to the National Comprehensive Cancer Network Guidelines, the primary treatment of early-stage cervical cancer is either surgery or radiotherapy. About 80% of women with early-stage disease (stage I–II) and 60% of women with stage III disease can be cured with effective treatment (including surgery and concurrent chemoradiotherapy) [3]. Nevertheless, patients who develop distant metastases (stage IVB) are rarely curable, with 5-year survival rate less than 20%. Even worse, approximately 50% of these patients show a fatal outcome within 1 year [4,5].

In light of previous studies, stage IVB cervical cancer was divided into two metastatic types. Lymphatic metastasis is defined as all the involved sites being lymph nodes outside of the pelvic, including para-aortic lymph nodes, while the other metastasis as hematogenous metastasis. As reported, hematogenous metastasis presented with a 5.3-fold higher risk of death than lymphatic metastasis [6]. For stage IVB cervical cancer patients, lung, liver, and bone are the most frequently involved sites of hematogenous metastasis. Despite brain metastasis constituting the most common type of intracranial tumor, those from cervical cancer is a rare event, with an incidence rate ranging from 0.4 to 2.3%. Brain metastasis is usually found later in the course of the disease with a median survival time of 1–8 months, often indicating an unfavorable prognosis [79]. There are currently no satisfactory treatment guidelines being established. The main management for brain metastasis is composed of surgery, local radiotherapy (whole brain radiation therapy [WBRT] and stereotactic radiosurgery [SRS]), systemic chemotherapy, or simply symptom control, similar to those for the other visceral metastasis [8,10].

Up to now, cervical cancer complicated with progressive distant metastasis indicates poor prognosis and causes increasing cancer-related mortality. Therefore, management with these patients remains a rather intractable challenge for physicians. As a small branch of Stage IVB cervical cancer, patients with brain metastasis were not systematically studied due to the paucity of clinical data and low level of the follow-up quality. Either retrospective or prospective clinical study concentrating on the analysis of risk factors and optimizing treatment plan is urgently desired for the sake of clinical application. In the present study, we retrieved information of cervical cancer patients with brain metastasis from the Surveillance, Epidemiology, and End Results (SEER) database. We analyzed the risk factors for developing brain metastasis and prognostic factors for overall survival (OS) of stage IVB cervical cancer with brain metastasis, which may contribute to clinical practice.

2 Materials and methods

2.1 Data source

The SEER database, a population-based registry, is sponsored by the National Cancer Institute. With 18 population-based cancer registries, the SEER program covers approximately 28% of the cancer registries from the United States [11]. The National Cancer Institute’s SEER*Stat software (version 8.3.5; Surveillance Research Program, National Cancer Institute SEER*Stat software, https://seer.cancer.gov/) was used to extract data after access permitted by signing an agreement. In view of that SEER database is an open public database, written informed consent cannot be assessed.

2.2 Study population

The retrospective clinical data of stage IVB cervical cancer patients from 2010 to 2019 was retrieved from the recent SEER-18 database. We limited this study to patients diagnosed between 2010 and 2019 as detailed information about site-specific metastasis was not recorded before 2010. Since 2010, the SEER data provide only four specific sites of metastases (bone, brain, liver, and lung). Other sites of metastasis are not documented currently. We included site codes C53.0-C53.1, C53.8, and C53.9 to identify primary cervical cancer based on the International Classification of Diseases for oncology, third Edition. The following baseline demographic and clinicopathologic characteristics of patients were collected: age at diagnosis; year of diagnosis, between 2010 and 2019; race, White, Black, or others including Asian or Pacific Islander; American Indian/Alaska Native; marital status, married or unmarried; tumor grade, I–II (including G1 or well-differentiated, G2 or moderately-differentiated), III–IV (including G3 or poorly-differentiated, G4 or undifferentiated or anaplastic); tumor histology including squamous cell carcinoma, adenocarcinoma, and other types including epithelial neoplasms, transitional cell papillomas and carcinomas, cystic, mucinous and serous neoplasms, complex epithelial neoplasms, complex mixed and stromal neoplasms, and unspecified neoplasms; American Joint Committee on Cancer (AJCC) stage; tumor size (the SEER database records the most accurate measurement of a solid primary tumor, usually measured on the surgical resection specimen); site-specific metastasis, including lung, bone, liver, and brain; cause-specific death classification; vital status; and survival months. Patients with visceral metastasis means patients were diagnosed with any site-specific metastasis including lung, bone, liver, and brain.

In addition, treatment data retrieved for each case included chemotherapy, radiotherapy, and surgery (including primary sites and metastatic sites). Patients were classified into two groups in our final analysis including with brain metastasis group and without brain metastasis group.

2.3 Statistical analysis

Data analysis was executed using R (version 4.2.1). The risk factors of developing brain metastasis were evaluated by logistic regression model with corresponding 95% confidence interval (95% CI). The primary outcome of the survival analysis was the OS (survival months), which was defined from the time of diagnosis of uterine cervical cancer to causes of cancer-specific death. Estimate of OS was performed using the Kaplan–Meier method and the log-rank test. The survival curves were made by Graph Pad Prism. Cox regression models were applied to estimate the impact of clinical factors for patients’ survival. A probability value of less than 0.05 was considered statistically significantly different.

3 Results

3.1 Risk analysis

The screening flow-chart is shown in Figure 1. Between 2010 and 2019, a total of 33,153 patients with cervical cancer were identified from the SEER database. Patients with more than one primary malignant tumor (N = 4,551) and clinical diagnosis only or direct visualization without microscopic confirmation (N = 83) were excluded from this study. In addition, patients who died of other causes (N = 1,260), with survival months of 0 (N = 802) or unknown survival months (N = 174), and unknown brain metastasis information (N = 807) were also filtered out. Following the screening procedure, a total of 25,476 cervical cancer patients were finally included in this study, among whom 88 patients (88/25,476, 0.35%) were diagnosed with brain metastasis, while 25,388 patients were diagnosed without brain metastasis (Table 1). To find out the independent risk factors in developing brain metastasis in patients with cervical cancer, the multivariate logistic regression analysis was performed. Patients with lung metastasis (without vs with, P < 0.001, odds ratio [OR] = 1.037, 95% CI = 1.033–1.041), liver metastasis (without vs with, P < 0.001, OR = 1.134, 95% CI = 1.109–1.161), or bone metastasis (without vs with, P < 0.001, OR = 1.025, 95% CI = 1.020–1.030) had a 1.037-, 1.134-, and 1.025-fold increased risk of brain metastases, respectively (Table 1). Nevertheless, age older than 65 (≤39 vs ≥65, P = 0.001, OR = 0.996, 95% CI = 0.994–0.999) were associated with decreased risk of developing brain metastasis, with a 0.4% risk reduction.

Figure 1 
                  Flowchart of this study.
Figure 1

Flowchart of this study.

Table 1

Baseline demographic and clinicopathologic characteristics and risk analysis in cervical cancer patients developing brain metastasis

Characteristic (%) Without brain metastasis (n = 25,388) With brain metastasis (n = 88) Multivariate analysis
Age at diagnosis
≤39 11,005 (43.3) 32 (36.4) 1
>40, ≤64 10,479 (41.3) 44 (50.0) 0.999 (0.998–1.001) 0.3
≥65 3,904 (15.4) 12 (13.6) 0.996 (0.994–0.999) 0.001
Race
White 18,876 (74.4) 69 (78.4) 1
Black 3,197 (12.6) 13 (14.8) 0.999 (0.997–1.001) 0.468
Others* 2,987 (11.8) 5 (5.7) 0.998 (0.996–1.001) 0.133
Unknown 328 (1.3) 1 (1.1)
Marital status
Unmarried 12,839 (50.6) 45 (51.1) 1
Married 11,023 (43.4) 36 (40.9) 1.000 (0.999–1.002) 0.723
Unknown 1,526 (6.0) 7 (8.0)
Grade
I–II 8,736 (34.4) 12 (13.6) 1
III–IV 5,996 (23.6) 36 (40.9) 1.002 (0.999–1.004) 0.082
Unknown 10,656 (42.0) 40 (45.5)
Histology
SCC 16,486 (64.9) 53 (60.2) 1
Adenocarcinoma 6,105 (24.0) 17 (19.3) 1.000 (0.998–1.002) 0.825
Other* 2,797 (11.0) 18 (20.5) 1.001 (0.998–1.003) 0.509
Tumor size (cm)
≤2 10,486 (41.3) 22 (25.0) 1
>2, ≤4 42 (0.2) 0 (0.0) 0.999 (0.982–1.017) 0.916
>4 66 (0.3) 1 (1.1) 1.014 (1.000–1.028) 0.054
Unknown 14,794 (58.3) 65 (73.9)
AJCC T
T1 8,149 (32.1) 5 (5.7) 1
T2 3,135 (12.3) 13 (14.8) 1.002 (1.000–1.004) 0.11
T3 2,225 (8.8) 15 (17.0) 1.000 (0.997–1.003) 0.795
T4 523 (2.1) 5 (5.7) 1.000 (0.995–1.006) 0.866
Unknown 11,356 (44.7) 50 (56.8)
AJCC N
N0 10,316 (40.6) 12 (13.6) 1
N1 3,697 (14.6) 31 (35.2) 1.002 (1.000–1.004) 0.106
Unknown 11,375 (44.8) 45 (51.1)
Lung metastasis
No 24,380 (96.0) 38 (43.2) 1
Yes 957 (3.8) 46 (52.3) 1.037 (1.033–1.041) <0.001
Unknown 51 (0.2) 4 (4.5)
Liver metastasis
No 24,874 (98.0) 69 (78.4) 1
Yes 493 (1.9) 15 (17.0) 1.134 (1.109–1.161) <0.001
Unknown 21 (0.1) 4 (4.5)
Bone metastasis
No 24,802 (97.7) 60 (68.2) 1
Yes 572 (2.3) 27 (30.7) 1.025 (1.020–1.030) <0.001
Unknown 14 (0.1) 1 (1.1)

Abbreviations: SCC, squamous cell carcinoma; OR, odds ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer. The results were adjusted for age at diagnosis, race, grade, marital status, histology, AJCC T, AJCC N, lung or liver or bone metastasis, and the significant results in bold, if P < 0.05. *Race – others (Asian or Pacific Islander; American Indian/Alaska Native); histology – others (epithelial neoplasms, NOS; transitional cell papillomas and carcinomas; cystic, mucinous and serous neoplasms; complex epithelial neoplasms; complex mixed and stromal neoplasms; unspecified neoplasms). The results are in bold if P < 0.05.

3.2 Survival analysis

In order to analyze the impact of different visceral metastasis sites on survival, we focused on patients with stage IVB cervical cancer. As expected, patients with brain metastasis indicated a poor prognosis with a median survival month of 6, which is much shorter compared with the lung (9 months) or liver (8.5 months) or bone (11 months) metastasis group. In consistent with above results, we observed an inferior survival outcome of patients with brain metastasis (P < 0.001, hazards ratio [HR] = 2.84, 95% CI = 1.71–4.72) in multivariate analysis, with a 2.84-fold elevated risk of death compared with patients without brain metastasis (Table 2, Figure 2).

Table 2

Survival analysis of stage IVB cervical cancer patients with visceral metastasis

Characteristic Survival months (median) Univariate analysis Multivariate analysis
Visceral metastasis HR (95% CI) P-value HR (95%CI) P-value
None 17 1 1
Lung 9 1.85 (1.61–2.12) <0.001 1.38 (1.20–1.59) <0.001
Liver 8.5 2.13 (1.73–2.62) <0.001 1.79 (1.44–2.22) <0.001
Bone 11 1.75 (1.44–2.12) <0.001 1.67 (1.37–2.04) <0.001
Brain 6 3.18 (1.93–5.22) <0.001 2.84 (1.71–4.72) <0.001
More than one site 5 2.91 (2.55–3.32) <0.001 2.36 (2.06–2.71) <0.001

The multivariate results were adjusted for age at diagnosis, race, marital status, grade, histology, AJCC T, AJCC N, surgery, chemoradiotherapy and the significant results are in bold, if P < 0.05.

Figure 2 
                  Kaplan–Meier analyses with the log-rank for the impact of different visceral metastasis on OS in stage IVB cervical cancer patients.
Figure 2

Kaplan–Meier analyses with the log-rank for the impact of different visceral metastasis on OS in stage IVB cervical cancer patients.

Furthermore, to clarify the association of demographic and clinicopathologic characteristics with cancer-specific OS in stage IVB cervical cancer patients with brain metastasis, univariate and multivariate analysis were performed for adjusting variants including age at diagnosis, race, marital status, grade, histology, tumor size, AJCC stage, visceral metastasis, surgery, radiotherapy, and chemotherapy (Table 3). In univariate analysis, we found several factors significantly associated with OS. Tumor grade (I–II vs III–IV, P = 0.042, HR = 0.49, 95% CI = 0.25–0.97) was associated with a 51% reduction in the risk of death. Conversely, the presence of bone metastasis (with vs without, P = 0.001, HR = 2.30, 95% CI = 1.41–3.77) was linked to a 2.30-fold increase in the risk of death. Additionally, patients receiving chemoradiotherapy (with vs without, P = 0.018, HR = 0.37, 95% CI = 0.20–0.68) had a 63% lower risk of death compared to those not receiving this treatment (Table 3, Figure 3). In multivariate analysis, patients with lower tumor grade (P = 0.001, HR = 0.27, 95% CI = 0.09–0.76), AJCC T3 stage (P = 0.005, HR = 11.17, 95% CI = 2.10–59.45), with bone metastasis (P = 0.007, HR = 2.74, 95% CI = 1.33–5.67) demonstrated worse OS outcomes, with a 3.7-, 11.17- and 2.74-fold higher risk of death, respectively. Moreover, chemoradiotherapy tended to prolong the survival of stage IVB cervical cancer patients with brain metastasis (P = 0.001, HR = 0.17, 95% CI = 0.06–0.48), with an 83% reduction in the risk of death.

Table 3

Association of demographic and clinicopathologic characteristics with cancer-specific OS in cervical cancer patients with brain metastasis

Characteristic Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age at diagnosis
≤39 1 1
>40, ≤64 0.91 (0.55–1.50) 0.708 1.46 (0.78–2.76) 0.241
≥65 0.99 (0.48–2.06) 0.979 1.04 (0.40–2.70) 0.939
Race
White 1 1
Black 0.92 (0.47–1.80) 0.801 0.66 (0.25–1.76) 0.406
Others* 0.85 (0.34–2.12) 0.727 1.18 (0.36–3.89) 0.783
Marital status
Unmarried 1
Married 0.94 (0.59–1.51) 0.802 1.50 (0.75–3.00) 0.25
Grade
I–II 1 1
III–IV 0.49 (0.25–0.97) 0.042 0.27 (0.09–0.76) 0.013
Histology
SCC 1 1
Adenocarcinoma 0.71 (0.39–1.32) 0.285 0.56 (0.21–1.49) 0.25
Other 1.10 (0.61–1.97) 0.755 1.36 (0.60–3.11) 0.463
Tumor size (cm)
≤2 1 1
>2, ≤4 NA NA NA NA
>4 0.99 (0.13–7.39) 0.995 0.50 (0.03–7.92) 0.624
AJCC T
T1 1 1
T2 1.92 (0.68–5.42) 0.218 4.54 (0.86–24.03) 0.076
T3 1.33 (0.48–3.67) 0.584 11.17 (2.10–59.45) 0.005
T4 2.03 (0.58–7.14) 0.27 1.85 (0.36–9.33) 0.459
AJCC N
N0 1
N1 1.20 (0.60–2.40) 0.6 1.65 (0.68–4.00) 0.595
Lung metastasis
No 1 1
Yes 1.11 (0.69–1.77) 0.673 0.95 (0.46–1.97) 0.9
Liver metastasis
No 1 1
Yes 1.22 (0.68–2.21) 0.507 1.25 (0.52–3.04) 0.617
Bone metastasis
No 1 1
Yes 2.30 (1.41–3.77) 0.001 2.74 (1.33–5.67) 0.006
Surgery
No 1 1
Yes 0.64 (0.28–1.48) 0.301 0.87 (0.29–2.60) 0.808
Chemoradiotherapy
No 1 1
Chemotherapy 0.56 (0.25–1.25) 0.157 0.70 (0.20–2.49) 0.58
Radiotherapy 0.76 (0.34–1.69) 0.501 0.48 (0.17–1.43) 0.187
Chemoradiotherapy 0.37 (0.20–0.68) 0.002 0.17 (0.06–0.48) 0.001

Abbreviations: OS, overall survival; SCC, squamous cell carcinoma; HR, hazards ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer. The multivariate results were adjusted for age at diagnosis, race, marital status, grade, histology, AJCC T, AJCC N, lung or liver or bone metastasis, surgery, radiotherapy, chemotherapy and the significant results in bold, if P < 0.05. *Race – others (Asian or Pacific Islander; American Indian/Alaska Native) Histology – others (epithelial neoplasms, NOS; transitional cell papillomas and carcinomas; cystic, mucinous and serous neoplasms; complex epithelial neoplasms; complex mixed and stromal neoplasms; unspecified neoplasms). Surgery – Yes (surgery of primary sites).

Figure 3 
                  Kaplan–Meier analyses with the log-rank for OS in stage IVB cervical cancer patients with brain metastasis: (a) grade I–II vs III–IV, (b) with vs without bone metastasis, and (c) with vs without chemotherapy.
Figure 3

Kaplan–Meier analyses with the log-rank for OS in stage IVB cervical cancer patients with brain metastasis: (a) grade I–II vs III–IV, (b) with vs without bone metastasis, and (c) with vs without chemotherapy.

3.3 Stratified analysis

In clinical practice, multiple factors may influence the treatment decision. To select the optimal patients with brain metastasis amenable to chemoradiotherapy, the stratified survival analysis was also conducted according to sub-classification of stage IVB cervical cancer patients with brain metastasis. We performed the multivariate Cox regression analysis of chemoradiotherapy with adjusted clinical variables including age at diagnosis, race, marital status, grade, histology, AJCC T stage, AJCC N stage, visceral metastasis as shown in Table 4. In sum, chemoradiotherapy was recommended for white people (P < 0.001, HR = 0.04, 95% CI = 0.02–0.08) with a 96% reduction in the risk of death, significantly reducing the risk of death by 98% for squamous cell carcinoma (P < 0.001, HR = 0.02, 95% CI = 0.00–0.13) and by 99% for adenocarcinoma (P < 0.001, HR = 0.01, 95% CI = 9.39 × 10−4–0.04). Additionally, for patients with lymphatic metastasis (P = 0.001, HR = 2.36 × 10−3, 95% CI = 9.87 × 10−4–0.01), the treatment reduces the mortality risk by approximately 99.764%. In cases of lung metastasis (P < 0.001, HR = 0.02, 95% CI = 0.002–0.14), the death risk is also reduced by 98%. For patients without liver metastasis (P = 0.005, HR = 0.31, 95% CI = 0.14–0.70), the reduction in mortality risk is 69%. These benefits have been observed across all age groups, marital statuses, and event states of bone metastasis.

Table 4

Stratified analysis for associations between chemoradiotherapy and OS of stage IVB cervical cancer patients with brain metastasis

Treatment
Select covariates Total/death HR 95% CI P
Age at diagnosis
≤39 32/27 1.99 × 10−3 1.87 × 10−5–0.21 0.009
>40, ≤64 44/39 0.03 0.02–0.06 <0.001
≥65 12/10 NA NA NA
Race
White 69/60 0.04 0.02–0.08 <0.001
Black 10/13 NA NA NA
Others* 5/0 NA NA NA
Marital status
Unmarried 45/40 0.04 0.01–0.23 <0.001
Married 36/30 0.02 1.21 × 10−3–0.39 0.009
Grade
I–II 12/12 NA NA NA
III–IV 36/34 6.67 × 10−6 4.11 × 10−8–1.08 × 10−3 <0.001
Histology
SCC 53/48 0.02 0.00–0.13 <0.001
Adenocarcinoma 17/13 0.01 9.39 × 10−4–0.04 <0.001
Other 18/15 1 0.29–3.45 1
Tumor size (cm)
≤2 22/22 1 0.27–3.74 1
>2, ≤4 1/1 NA NA NA
>4 65/53 NA NA NA
AJCC T
T1 5/5 NA NA NA
T2 13/13 NA NA NA
T3 15/15 1 0.06–15.99 1
T4 5/5 NA NA NA
AJCC N
N0 12/1 NA NA NA
N1 31/31 2.36 × 10−3 9.87 × 10−4–0.01 <0.001
Lung metastasis
No 38/31 1.02 0.07–14.00 0.99
Yes 46/41 0.02 0.002–0.14 <0.001
Liver metastasis
No 69/58 0.31 0.14–0.70 0.005
Yes 15/14 1 0.00-INF 1
Bone metastasis
No 60/48 0.12 0.03–0.50 0.003
Yes 27/27 1.16 × 10−63 3.45 × 10−64–3.88 × 10−63 <0.001

Abbreviations: OS, overall survival; SCC, squamous cell carcinoma; HR, hazards ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer. The results were adjusted for age at diagnosis, race, marital status, grade, histology, AJCC T, AJCC N, lung or liver or bone metastasis, surgery, radiotherapy, chemotherapy and the significant results in bold, if P < 0.05. *Race – others (Asian or Pacific Islander; American Indian/Alaska Native). Histology – others (epithelial neoplasms, NOS; transitional cell papillomas and carcinomas; cystic, mucinous and serous neoplasms; complex epithelial neoplasms; complex mixed and stromal neoplasms; unspecified neoplasms).

4 Discussion

In this study, between 2010 and 2019, 88 stage IVB cervical cancer patients initially diagnosed with brain metastasis from the SEER database were available for analysis. The case numbers were much more substantial than in previous studies, which were mostly case reports [12,13]. This resulted in improved credibility of our research. Subsequently, we retrospectively evaluated the risk factors for developing brain metastasis and prognostic factors for OS in stage IVB cervical cancer patients with brain metastasis. To our knowledge, this study covered risk, survival, and treatment analysis for the first time and found that survival advantage significantly favors patients who underwent chemoradiotherapy in stage IVB cervical cancer patients with brain metastasis. These results were of important reference value for clinical diagnosis and treatment. In this study, the incidence rate of initially diagnosed brain metastasis was 0.35% (88/25,476) between 2010 and 2019, which was much less than recurrence with brain metastasis (1.2%). The result indicated possible different clinical characters between the two types [14,15]. Logically, brain metastasis deserves more detailed sub-classification and treatment modality optimization in clinical practice. Previous studies mainly focused on recurrence manifested with brain metastasis [13,16], while this study concentrated on initially diagnosed brain metastasis. Thereby, our research is of great novelty.

Further analysis revealed that patients with lung metastasis, liver metastasis, or bone metastasis were more likely to develop brain metastasis. The reason for this phenomenon may be that once cervical cancer patients developed liver, lung, or bone metastasis, cancer cells had already appeared in the blood, making it easier to penetrate the blood–brain barrier [10,17]. Surprisingly, in this study, age older than 65 were associated with decreased risk of developing brain metastasis. It seemed reasonable because previous study reported a high rate of cervical adenocarcinoma in younger patients with an increasing risk of lymph node metastasis, which resulted in a reduced survival rate compared with older women [18]. Brain metastasis can occur in any pathological type [1921]. Pervious study observed an increased probability for developing brain metastasis in small cell carcinoma (SCC) of cervical cancer, which may be associated with a poor prognosis. Kim et al. reported a different outcome that SCC achieved more survival than other histology, which could be explained by the fact that cervical cancer patients with SCC were more likely to receive multimodal therapy [9]. However, in this study we found no statistical relationship between histology types and the occurrence and prognosis in stage IVB cervical cancer patients with brain metastasis.

Previous researchers reported that patients without brain metastasis are associated with a better prognosis than those with brain metastasis, whose median survival time was 1–8 months [7,8,19,2225]. In this study, as expected, patients with brain metastasis indicated worst clinical outcome with a median survival month of 6, which is much shorter compared with the lung (9 months) or liver (8.5 months) or bone (11 months) metastasis group. Previous study showed that the median OS for only lung, only liver, only bone, and only brain metastasis was 5, 5, 4, and 3 months, respectively, which was consistent with our results [26].

Additionally, we concluded that patients with grade I–II demonstrated worse OS outcomes than those with grade III–IV. As previous studies showed, brain metastasis was more common in moderately differentiated cervical cancer rather than in well, poorly, and undifferentiated tumors [26]. This might partially explain our results. Further analysis demonstrated that patients synchronously diagnosed with bone and brain metastasis presented with worse clinical outcomes. We supposed that the reason behind this phenomenon was that cervical cancer patients with liver metastasis and with lung metastasis was available for much more treatment choice including surgical resection, chemotherapy, or radiotherapy than with bone metastasis [10,27]. The main treatment modality for patients with bone metastasis was either radiotherapy or chemotherapy. And indications for surgery in these patients were difficult to determine [28]. We retrieved literature and found that only two patients with bone metastasis were treated surgically and complete resection was not possible [28]. In addition to the above-mentioned survival factors, the prognosis of cervical cancer with brain metastasis was also reported to be affected by many factors such as age, pathological type, control of primary cervical lesions, number of brain metastasis and tumor size, extracranial metastasis, time interval from diagnosis of cervical cancer to the diagnosis of brain metastasis, extracranial metastasis, and therapeutic factors [7]. For example, being younger than 50 years of age, in good physical condition, with single brain metastases, and without extracranial metastases was associated with a good prognosis [19]. And presenting extracerebral metastasis, diameter of the largest brain metastasis <2 cm, time between SCC diagnosis and brain metastasis <1 year indicated worse prognosis [8].

As for treatment, we found that chemoradiotherapy could prolong the survival of stage IVB cervical cancer patients with brain metastasis. This result was consistent with previous studies. Multimodal therapy can prolong OS [13,29], consisting of surgery, SRS, WBRT, and chemotherapy. In our research, we found that chemoradiotherapy tended to prolong the survival of stage IVB cervical cancer patients with brain metastasis. Some literature has also found that bevacizumab, when used in conjunction with standard chemotherapy, can increase clinical benefits for cancer patients (such as OS, progression-free survival, and response rates). This suggests that targeted therapies such as anti-angiogenic agents may be considered for cervical cancer patients with brain metastasis to improve OS [30]. However, from literature review, the best option for single brain metastasis from cervical cancer is neurosurgical resection followed by radiation therapy. WBRT is considered the primary palliation treatment for patients with multiple or inoperable brain metastasis [16]. Additionally, it has been indicated that for inoperable ovarian cancer patients, neoadjuvant chemotherapy is a safe and effective alternative. Therefore, for inoperable cervical cancer patients with brain metastasis, neoadjuvant chemotherapy might be employed with the intention of achieving tumor shrinkage before surgical resection; however, this requires further research for validation [31]. Overall, surgical resection combined with radiotherapy can provide the most satisfactory treatment effect for patients with single brain metastasis without systemic disease. While in terms of multiple brain metastases, the use of palliative brain radiotherapy is an optimal choice. Chemotherapy is suitable for multiple brain metastases accompanied with other organ metastasis and systemic disease [13,32,33]. Since information about surgery is not available in the SEER database, further studies are expected to investigate the effect of surgical resection on survival outcomes in patients with brain metastasis.

We must admit that there are some limitations to this study. As this study is a retrospective study, it is inevitable that there will be some bias. In addition, the cases included in this study were strictly screened, and a large number of patients were excluded from the analysis, resulting in missing or incomplete information and further information bias. We do not have access to detailed treatment information of cervical cancer patients, including the type of surgery, radiation dose, chemotherapy drugs, detailed information, for example the number of brain metastasis and so on, which is a major limitation of this study. Due to the limited number of patients, especially those with brain metastases, larger sample sizes and prospective further studies are needed for more comprehensive and comparative analyses. For all this, the study analyzed clinical characteristics of cervical cancer patients with brain metastasis and assessed prognostic factors influencing OS in patients which have certain guiding significance for clinical practice.

In conclusion, the occurrence of brain metastasis in cervical cancer patients indicated poor prognosis. We need more research studies to verify our conclusion and provide more appropriate treatment plans, so as to prolong the survival time and improve the quality of life of such patients.


# These authors contribute equally to this work.

tel: +86(0)2164175590, fax: +86(0)21-64172585

Acknowledgments

The authors acknowledge the efforts of the SEER Program for providing the available cervical cancer data.

  1. Funding information: This study was supported by the National Natural Science Foundation of China (Grant Nos 82274278 and 82102718) and the Medical Scientific Research Project in Xuhui District, Shanghai (SHXH202136).

  2. Author contributions: J.W., H.R.L., and X.C. designed the study. J.W., Q.X., and H.R.L. collected and analyzed the data. H.X.H. and Y.Y.P. performed data validation. J.W. and H.R.L. wrote the article. H.R.L. and X.C. reviewed and edited the manuscript. J.W., H.R.L., H.X.H., and Y.Y.P. revised the manuscript. All authors read and approved the manuscript.

  3. Conflict of interest: The authors report no conflict of interest in this work.

  4. Data availability statement: Data from SEER database are available in the SEER cancer registry (https://seer.cancer.gov).

References

[1] Olawaiye AB, Baker TP, Washington MK, Mutch DG. The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. CA Cancer J Clin. 2021;71(4):287–98.10.3322/caac.21663Suche in Google Scholar PubMed

[2] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA: A Cancer J Clin. 2021;71(3):209–49.10.3322/caac.21660Suche in Google Scholar PubMed

[3] Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(1):64–84.10.6004/jnccn.2019.0001Suche in Google Scholar PubMed

[4] Li H, Pang Y, Cheng X. Surgery of primary sites for stage IVB cervical cancer patients receiving chemoradiotherapy: a population-based study. J Gynecol Oncol. 2020;31(1):e8.10.3802/jgo.2020.31.e8Suche in Google Scholar PubMed PubMed Central

[5] Saleh M, Virarkar M, Javadi S, Elsherif SB, de Castro Faria S, Bhosale P. Cervical Cancer: 2018 Revised International Federation of Gynecology and Obstetrics Staging System and the Role of Imaging. AJR Am J Roentgenol. 2020;214(5):1182–95.10.2214/AJR.19.21819Suche in Google Scholar PubMed

[6] Kim K, Cho SY, Kim BJ, Kim MH, Choi SC, Ryu SY. The type of metastasis is a prognostic factor in disseminated cervical cancer. J Gynecol Oncol. 2010;21(3):186–90.10.3802/jgo.2010.21.3.186Suche in Google Scholar PubMed PubMed Central

[7] Sun S, Lian X, Liu X, Ma J, Hou X, Zhang F, et al. Multimodal therapy is a better choice for patients with brain metastasis from cervical cancer. Cancer Manag Res. 2020;12:12395–402.10.2147/CMAR.S283673Suche in Google Scholar PubMed PubMed Central

[8] de Brito Rangel J, Giglio AG, Cardozo CL, Bergmann A, Thuler LCS. Prognostic factors for brain metastasis in women presenting cervical cancer. J Neurooncol. 2022;159(2):469–77.10.1007/s11060-022-04082-9Suche in Google Scholar PubMed

[9] Kim H, Lee KK, Heo MH, Kim JY. The prognostic factors influencing overall survival in uterine cervical cancer with brain metastasis. Korean J Intern Med. 2019;34(6):1324–32.10.3904/kjim.2018.051Suche in Google Scholar PubMed PubMed Central

[10] Liu H, Ye X, Li D, Yao Q, Li Y. Incidence, clinical risk and prognostic factors for liver metastasis in patients with cervical cancer: a population-based retrospective study. BMC Cancer. 2021;21(1):421.10.1186/s12885-021-08127-6Suche in Google Scholar PubMed PubMed Central

[11] Doll KM, Rademaker A, Sosa JA. Practical guide to surgical data sets: surveillance, epidemiology, and end results (SEER) database. JAMA Surg. 2018;153(6):588–9.10.1001/jamasurg.2018.0501Suche in Google Scholar PubMed

[12] Setoodeh R, Hakam A, Shan Y. Cerebral metastasis of cervical cancer, report of two cases and review of the literature. Int J Clin Exp Pathol. 2012;5(7):710–4.Suche in Google Scholar

[13] Fetcko K, Gondim DD, Bonnin JM, Dey M. Cervical cancer metastasis to the brain: a case report and review of literature. Surg Neurol Int. 2017;8:181.10.4103/sni.sni_111_17Suche in Google Scholar PubMed PubMed Central

[14] Cormio G, Pellegrino A, Landoni F, Regallo M, Zanetta G, Colombo A, et al. Brain metastases from cervical carcinoma. Tumori. 1996;82(4):394–6.10.1177/030089169608200420Suche in Google Scholar PubMed

[15] Chura JC, Shukla K, Argenta PA. Brain metastasis from cervical carcinoma. Int J Gynecol Cancer. 2007;17(1):141–6.10.1111/j.1525-1438.2007.00808.xSuche in Google Scholar PubMed

[16] Park SH, Ro DY, Park BJ, Kim YW, Kim TE, Jung JK, et al. Brain metastasis from uterine cervical cancer. J Obstet Gynaecol Res. 2010;36(3):701–4.10.1111/j.1447-0756.2010.01219.xSuche in Google Scholar PubMed

[17] Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168(4):670–91.10.1016/j.cell.2016.11.037Suche in Google Scholar PubMed PubMed Central

[18] Yang L, Jia X, Li N, Chen C, Liu Y, Wang H. Comprehensive clinic-pathological characteristics of cervical cancer in southwestern China and the clinical significance of histological type and lymph node metastases in young patients. PLoS One. 2013;8(10):e75849.10.1371/journal.pone.0075849Suche in Google Scholar PubMed PubMed Central

[19] Hwang JH, Yoo HJ, Lim MC, Seo SS, Kang S, Kim JY, et al. Brain metastasis in patients with uterine cervical cancer. J Obstet Gynaecol Res. 2013;39(1):287–91.10.1111/j.1447-0756.2012.01927.xSuche in Google Scholar PubMed

[20] Viswanathan AN, Deavers MT, Jhingran A, Ramirez PT, Levenback C, Eifel PJ. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol. 2004;93(1):27–33.10.1016/j.ygyno.2003.12.027Suche in Google Scholar PubMed

[21] Weed Jr JC, Graff AT, Shoup B, Tawfik O. Small cell undifferentiated (neuroendocrine) carcinoma of the uterine cervix. J Am Coll Surg. 2003;197(1):44–51.10.1016/S1072-7515(03)00120-0Suche in Google Scholar PubMed

[22] Teke F, Tunc SY, Teke M, Turan Y, Urakci Z, Eren B, et al. The impact of the stage and tumor size on rare brain metastasis of cervical cancer. Turk Neurosurg. 2016;26(6):818–23.Suche in Google Scholar

[23] Rangel JB, Giglio AG, Cardozo CL, Bergmann A, Thuler LCS. Incidence and risk factors for the development of cerebral metastasis in cervical cancer patients. J Gynecol Oncol. 2022;33(5):e58.10.3802/jgo.2022.33.e58Suche in Google Scholar PubMed PubMed Central

[24] Gardner AB, Charo LM, Mann AK, Kapp DS, Eskander RN, Chan JK. Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes. Clin Exp Metastasis. 2020;37(1):107–13.10.1007/s10585-019-10007-0Suche in Google Scholar PubMed

[25] Hayashi N, Takahashi H, Hasegawa Y, Higuchi F, Takahashi M, Makino K, et al. A nationwide multi-institutional retrospective study to identify prognostic factors and develop a graded prognostic assessment system for patients with brain metastases from uterine corpus and cervical cancer. BMC Cancer. 2017;17(1):397.10.1186/s12885-017-3358-6Suche in Google Scholar PubMed PubMed Central

[26] Qiu MZ, Shi SM, Chen ZH, Yu HE, Sheng H, Jin Y, et al. Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: a SEER-based study. Cancer Med. 2018;7(8):3662–72.10.1002/cam4.1661Suche in Google Scholar PubMed PubMed Central

[27] Chen X, Chen L, Zhu H, Tao J. Risk factors and prognostic predictors for cervical cancer patients with lung metastasis. J Cancer. 2020;11(20):5880–9.10.7150/jca.46258Suche in Google Scholar PubMed PubMed Central

[28] Makino H, Nishio S, Tsubamoto H, Shimada M, Nishikawa R, Kai K, et al. Treatment and prognosis of bone metastasis from cervical cancer (KCOG-G1202s). J Obstet Gynaecol Res. 2016;42(6):701–6.10.1111/jog.12956Suche in Google Scholar PubMed

[29] Kato MK, Tanase Y, Uno M, Ishikawa M, Kato T. Brain metastases from uterine cervical and endometrial cancer. Cancers (Basel). 2021;13(3):519.10.3390/cancers13030519Suche in Google Scholar PubMed PubMed Central

[30] Chitoran E, Rotaru V, Ionescu SO, Gelal A, Capsa CM, Bohiltea RE, et al. Bevacizumab-based therapies in malignant tumors-real-world data on effectiveness, safety, and cost. Cancers. 2024;16(14):2590.10.3390/cancers16142590Suche in Google Scholar PubMed PubMed Central

[31] Margioula-Siarkou C, Petousis S, Papanikolaou A, Gullo G, Margioula-Siarkou G, Laganà AS, et al. Neoadjuvant chemotherapy in advanced-stage ovarian cancer – state of the art. Przeglad menopauzalny = Menopause Review. 2022;21(4):272–5.10.5114/pm.2022.124018Suche in Google Scholar PubMed PubMed Central

[32] Robinson JB, Morris M. Cervical carcinoma metastatic to the brain. Gynecol Oncol. 1997;66(2):324–6.10.1006/gyno.1997.4763Suche in Google Scholar PubMed

[33] Li H, Wu X, Cheng X. Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 2016;27(4):e43.10.3802/jgo.2016.27.e43Suche in Google Scholar PubMed PubMed Central

Received: 2024-07-17
Revised: 2025-02-17
Accepted: 2025-02-18
Published Online: 2025-08-22

© 2025 the author(s), published by De Gruyter

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

  1. Research Articles
  2. Network pharmacological analysis and in vitro testing of the rutin effects on triple-negative breast cancer
  3. Impact of diabetes on long-term survival in elderly liver cancer patients: A retrospective study
  4. Knockdown of CCNB1 alleviates high glucose-triggered trophoblast dysfunction during gestational diabetes via Wnt/β-catenin signaling pathway
  5. Risk factors for severe adverse drug reactions in hospitalized patients
  6. Analysis of the effect of ALA-PDT on macrophages in footpad model of mice infected with Fonsecaea monophora based on single-cell sequencing
  7. Development and validation of headspace gas chromatography with a flame ionization detector method for the determination of ethanol in the vitreous humor
  8. CMSP exerts anti-tumor effects on small cell lung cancer cells by inducing mitochondrial dysfunction and ferroptosis
  9. Predictive value of plasma sB7-H3 and YKL-40 in pediatric refractory Mycoplasma pneumoniae pneumonia
  10. Antiangiogenic potential of Elaeagnus umbellata extracts and molecular docking study by targeting VEGFR-2 pathway
  11. Comparison of the effectiveness of nurse-led preoperative counseling and postoperative follow-up care vs standard care for patients with gastric cancer
  12. Comparing the therapeutic efficacy of endoscopic minimally invasive surgery and traditional surgery for early-stage breast cancer: A meta-analysis
  13. Adhered macrophages as an additional marker of cardiomyocyte injury in biopsies of patients with dilated cardiomyopathy
  14. Association between statin administration and outcome in patients with sepsis: A retrospective study
  15. Exploration of the association between estimated glucose disposal rate and osteoarthritis in middle-aged and older adults: An analysis of NHANES data from 2011 to 2018
  16. A comparative analysis of the binary and multiclass classified chest X-ray images of pneumonia and COVID-19 with ML and DL models
  17. Lysophosphatidic acid 2 alleviates deep vein thrombosis via protective endothelial barrier function
  18. Transcription factor A, mitochondrial promotes lymph node metastasis and lymphangiogenesis in epithelial ovarian carcinoma
  19. Serum PM20D1 levels are associated with nutritional status and inflammatory factors in gastric cancer patients undergoing early enteral nutrition
  20. Hydromorphone reduced the incidence of emergence agitation after adenotonsillectomy in children with obstructive sleep apnea: A randomized, double-blind study
  21. Vitamin D replacement therapy may regulate sleep habits in patients with restless leg syndrome
  22. The first-line antihypertensive nitrendipine potentiated the therapeutic effect of oxaliplatin by downregulating CACNA1D in colorectal cancer
  23. Health literacy and health-related quality of life: The mediating role of irrational happiness
  24. Modulatory effects of Lycium barbarum polysaccharide on bone cell dynamics in osteoporosis
  25. Mechanism research on inhibition of gastric cancer in vitro by the extract of Pinellia ternata based on network pharmacology and cellular metabolomics
  26. Examination of the causal role of immune cells in non-alcoholic fatty liver disease by a bidirectional Mendelian randomization study
  27. Clinical analysis of ten cases of HIV infection combined with acute leukemia
  28. Investigating the cardioprotective potential of quercetin against tacrolimus-induced cardiotoxicity in Wistar rats: A mechanistic insights
  29. Clinical observation of probiotics combined with mesalazine and Yiyi Baitouweng Decoction retention enema in treating mild-to-moderate ulcerative colitis
  30. Diagnostic value of ratio of blood inflammation to coagulation markers in periprosthetic joint infection
  31. Sex-specific associations of sex hormone binding globulin and risk of bladder cancer
  32. Core muscle strength and stability-oriented breathing training reduces inter-recti distance in postpartum women
  33. The ERAS nursing care strategy for patients undergoing transsphenoidal endoscopic pituitary tumor resection: A randomized blinded controlled trial
  34. The serum IL-17A levels in patients with traumatic bowel rupture post-surgery and its predictive value for patient prognosis
  35. Impact of Kolb’s experiential learning theory-based nursing on caregiver burden and psychological state of caregivers of dementia patients
  36. Analysis of serum NLR combined with intraoperative margin condition to predict the prognosis of cervical HSIL patients undergoing LEEP surgery
  37. Commiphora gileadensis ameliorate infertility and erectile dysfunction in diabetic male mice
  38. The correlation between epithelial–mesenchymal transition classification and MMP2 expression of circulating tumor cells and prognosis of advanced or metastatic nasopharyngeal carcinoma
  39. Tetrahydropalmatine improves mitochondrial function in vascular smooth muscle cells of atherosclerosis in vitro by inhibiting Ras homolog gene family A/Rho-associated protein kinase-1 signaling pathway
  40. A cross-sectional study: Relationship between serum oxidative stress levels and arteriovenous fistula maturation in maintenance dialysis patients
  41. A comparative analysis of the impact of repeated administration of flavan 3-ol on brown, subcutaneous, and visceral adipose tissue
  42. Identifying early screening factors for depression in middle-aged and older adults: A cohort study
  43. Perform tumor-specific survival analysis for Merkel cell carcinoma patients undergoing surgical resection based on the SEER database by constructing a nomogram chart
  44. Unveiling the role of CXCL10 in pancreatic cancer progression: A novel prognostic indicator
  45. High-dose preoperative intraperitoneal erythropoietin and intravenous methylprednisolone in acute traumatic spinal cord injuries following decompression surgeries
  46. RAB39B: A novel biomarker for acute myeloid leukemia identified via multi-omics and functional validation
  47. Impact of peripheral conditioning on reperfusion injury following primary percutaneous coronary intervention in diabetic and non-diabetic STEMI patients
  48. Clinical efficacy of azacitidine in the treatment of middle- and high-risk myelodysplastic syndrome in middle-aged and elderly patients: A retrospective study
  49. The effect of ambulatory blood pressure load on mitral regurgitation in continuous ambulatory peritoneal dialysis patients
  50. Expression and clinical significance of ITGA3 in breast cancer
  51. Single-nucleus RNA sequencing reveals ARHGAP28 expression of podocytes as a biomarker in human diabetic nephropathy
  52. rSIG combined with NLR in the prognostic assessment of patients with multiple injuries
  53. Toxic metals and metalloids in collagen supplements of fish and jellyfish origin: Risk assessment for daily intake
  54. Exploring causal relationship between 41 inflammatory cytokines and marginal zone lymphoma: A bidirectional Mendelian randomization study
  55. Gender beliefs and legitimization of dating violence in adolescents
  56. Effect of serum IL-6, CRP, and MMP-9 levels on the efficacy of modified preperitoneal Kugel repair in patients with inguinal hernia
  57. Effect of smoking and smoking cessation on hematological parameters in polycythemic patients
  58. Pathogen surveillance and risk factors for pulmonary infection in patients with lung cancer: A retrospective single-center study
  59. Necroptosis of hippocampal neurons in paclitaxel chemotherapy-induced cognitive impairment mediates microglial activation via TLR4/MyD88 signaling pathway
  60. Celastrol suppresses neovascularization in rat aortic vascular endothelial cells stimulated by inflammatory tenocytes via modulating the NLRP3 pathway
  61. Cord-lamina angle and foraminal diameter as key predictors of C5 palsy after anterior cervical decompression and fusion surgery
  62. GATA1: A key biomarker for predicting the prognosis of patients with diffuse large B-cell lymphoma
  63. Influencing factors of false lumen thrombosis in type B aortic dissection: A single-center retrospective study
  64. MZB1 regulates the immune microenvironment and inhibits ovarian cancer cell migration
  65. Integrating experimental and network pharmacology to explore the pharmacological mechanisms of Dioscin against glioblastoma
  66. Trends in research on preterm birth in twin pregnancy based on bibliometrics
  67. Four-week IgE/baseline IgE ratio combined with tryptase predicts clinical outcome in omalizumab-treated children with moderate-to-severe asthma
  68. Single-cell transcriptomic analysis identifies a stress response Schwann cell subtype
  69. Acute pancreatitis risk in the diagnosis and management of inflammatory bowel disease: A critical focus
  70. Effect of subclinical esketamine on NLRP3 and cognitive dysfunction in elderly ischemic stroke patients
  71. Interleukin-37 mediates the anti-oral tumor activity in oral cancer through STAT3
  72. CA199 and CEA expression levels, and minimally invasive postoperative prognosis analysis in esophageal squamous carcinoma patients
  73. Efficacy of a novel drainage catheter in the treatment of CSF leak after posterior spine surgery: A retrospective cohort study
  74. Comprehensive biomedicine assessment of Apteranthes tuberculata extracts: Phytochemical analysis and multifaceted pharmacological evaluation in animal models
  75. Relation of time in range to severity of coronary artery disease in patients with type 2 diabetes: A cross-sectional study
  76. Dopamine attenuates ethanol-induced neuronal apoptosis by stimulating electrical activity in the developing rat retina
  77. Correlation between albumin levels during the third trimester and the risk of postpartum levator ani muscle rupture
  78. Factors associated with maternal attention and distraction during breastfeeding and childcare: A cross-sectional study in the west of Iran
  79. Mechanisms of hesperetin in treating metabolic dysfunction-associated steatosis liver disease via network pharmacology and in vitro experiments
  80. The law on oncological oblivion in the Italian and European context: How to best uphold the cancer patients’ rights to privacy and self-determination?
  81. The prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and prognostic nutritional index for survival in patients with colorectal cancer
  82. Factors affecting the measurements of peripheral oxygen saturation values in healthy young adults
  83. Comparison and correlations between findings of hysteroscopy and vaginal color Doppler ultrasonography for detection of uterine abnormalities in patients with recurrent implantation failure
  84. The effects of different types of RAGT on balance function in stroke patients with low levels of independent walking in a convalescent rehabilitation hospital
  85. Causal relationship between asthma and ankylosing spondylitis: A bidirectional two-sample univariable and multivariable Mendelian randomization study
  86. Correlations of health literacy with individuals’ understanding and use of medications in Southern Taiwan
  87. Correlation of serum calprotectin with outcome of acute cerebral infarction
  88. Comparison of computed tomography and guided bronchoscopy in the diagnosis of pulmonary nodules: A systematic review and meta-analysis
  89. Curdione protects vascular endothelial cells and atherosclerosis via the regulation of DNMT1-mediated ERBB4 promoter methylation
  90. The identification of novel missense variant in ChAT gene in a patient with gestational diabetes denotes plausible genetic association
  91. Molecular genotyping of multi-system rare blood types in foreign blood donors based on DNA sequencing and its clinical significance
  92. Exploring the role of succinyl carnitine in the association between CD39⁺ CD4⁺ T cell and ulcerative colitis: A Mendelian randomization study
  93. Dexmedetomidine suppresses microglial activation in postoperative cognitive dysfunction via the mmu-miRNA-125/TRAF6 signaling axis
  94. Analysis of serum metabolomics in patients with different types of chronic heart failure
  95. Diagnostic value of hematological parameters in the early diagnosis of acute cholecystitis
  96. Pachymaran alleviates fat accumulation, hepatocyte degeneration, and injury in mice with nonalcoholic fatty liver disease
  97. Decrease in CD4 and CD8 lymphocytes are predictors of severe clinical picture and unfavorable outcome of the disease in patients with COVID-19
  98. METTL3 blocked the progression of diabetic retinopathy through m6A-modified SOX2
  99. The predictive significance of anti-RO-52 antibody in patients with interstitial pneumonia after treatment of malignant tumors
  100. Exploring cerebrospinal fluid metabolites, cognitive function, and brain atrophy: Insights from Mendelian randomization
  101. Development and validation of potential molecular subtypes and signatures of ocular sarcoidosis based on autophagy-related gene analysis
  102. Widespread venous thrombosis: Unveiling a complex case of Behçet’s disease with a literature perspective
  103. Uterine fibroid embolization: An analysis of clinical outcomes and impact on patients’ quality of life
  104. Discovery of lipid metabolism-related diagnostic biomarkers and construction of diagnostic model in steroid-induced osteonecrosis of femoral head
  105. Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer
  106. Enhancing chronic back pain management: A comparative study of ultrasound–MRI fusion guidance for paravertebral nerve block
  107. Peptide CCAT1-70aa promotes hepatocellular carcinoma proliferation and invasion via the MAPK/ERK pathway
  108. Electroacupuncture-induced reduction of myocardial ischemia–reperfusion injury via FTO-dependent m6A methylation modulation
  109. Hemorrhoids and cardiovascular disease: A bidirectional Mendelian randomization study
  110. Cell-free adipose extract inhibits hypertrophic scar formation through collagen remodeling and antiangiogenesis
  111. HALP score in Demodex blepharitis: A case–control study
  112. Assessment of SOX2 performance as a marker for circulating cancer stem-like cells (CCSCs) identification in advanced breast cancer patients using CytoTrack system
  113. Risk and prognosis for brain metastasis in primary metastatic cervical cancer patients: A population-based study
  114. Comparison of the two intestinal anastomosis methods in pediatric patients
  115. Factors influencing hematological toxicity and adverse effects of perioperative hyperthermic intraperitoneal vs intraperitoneal chemotherapy in gastrointestinal cancer
  116. Endotoxin tolerance inhibits NLRP3 inflammasome activation in macrophages of septic mice by restoring autophagic flux through TRIM26
  117. Lateral transperitoneal laparoscopic adrenalectomy: A single-centre experience of 21 procedures
  118. Petunidin attenuates lipopolysaccharide-induced retinal microglia inflammatory response in diabetic retinopathy by targeting OGT/NF-κB/LCN2 axis
  119. Procalcitonin and C-reactive protein as biomarkers for diagnosing and assessing the severity of acute cholecystitis
  120. Factors determining the number of sessions in successful extracorporeal shock wave lithotripsy patients
  121. Development of a nomogram for predicting cancer-specific survival in patients with renal pelvic cancer following surgery
  122. Inhibition of ATG7 promotes orthodontic tooth movement by regulating the RANKL/OPG ratio under compression force
  123. A machine learning-based prognostic model integrating mRNA stemness index, hypoxia, and glycolysis‑related biomarkers for colorectal cancer
  124. Glutathione attenuates sepsis-associated encephalopathy via dual modulation of NF-κB and PKA/CREB pathways
  125. FAHD1 prevents neuronal ferroptosis by modulating R-loop and the cGAS–STING pathway
  126. Association of placenta weight and morphology with term low birth weight: A case–control study
  127. Investigation of the pathogenic variants induced Sjogren’s syndrome in Turkish population
  128. Nucleotide metabolic abnormalities in post-COVID-19 condition and type 2 diabetes mellitus patients and their association with endocrine dysfunction
  129. TGF-β–Smad2/3 signaling in high-altitude pulmonary hypertension in rats: Role and mechanisms via macrophage M2 polarization
  130. Ultrasound-guided unilateral versus bilateral erector spinae plane block for postoperative analgesia of patients undergoing laparoscopic cholecystectomy
  131. Profiling gut microbiome dynamics in subacute thyroiditis: Implications for pathogenesis, diagnosis, and treatment
  132. Delta neutrophil index, CRP/albumin ratio, procalcitonin, immature granulocytes, and HALP score in acute appendicitis: Best performing biomarker?
  133. Anticancer activity mechanism of novelly synthesized and characterized benzofuran ring-linked 3-nitrophenyl chalcone derivative on colon cancer cells
  134. H2valdien3 arrests the cell cycle and induces apoptosis of gastric cancer
  135. Prognostic relevance of PRSS2 and its immune correlates in papillary thyroid carcinoma
  136. Association of SGLT2 inhibition with psychiatric disorders: A Mendelian randomization study
  137. Motivational interviewing for alcohol use reduction in Thai patients
  138. Luteolin alleviates oxygen-glucose deprivation/reoxygenation-induced neuron injury by regulating NLRP3/IL-1β signaling
  139. Polyphyllin II inhibits thyroid cancer cell growth by simultaneously inhibiting glycolysis and oxidative phosphorylation
  140. Relationship between the expression of copper death promoting factor SLC31A1 in papillary thyroid carcinoma and clinicopathological indicators and prognosis
  141. CSF2 polarized neutrophils and invaded renal cancer cells in vitro influence
  142. Proton pump inhibitors-induced thrombocytopenia: A systematic literature analysis of case reports
  143. The current status and influence factors of research ability among community nurses: A sequential qualitative–quantitative study
  144. OKAIN: A comprehensive oncology knowledge base for the interpretation of clinically actionable alterations
  145. The relationship between serum CA50, CA242, and SAA levels and clinical pathological characteristics and prognosis in patients with pancreatic cancer
  146. Identification and external validation of a prognostic signature based on hypoxia–glycolysis-related genes for kidney renal clear cell carcinoma
  147. Engineered RBC-derived nanovesicles functionalized with tumor-targeting ligands: A comparative study on breast cancer targeting efficiency and biocompatibility
  148. Relationship of resting echocardiography combined with serum micronutrients to the severity of low-gradient severe aortic stenosis
  149. Effect of vibration on pain during subcutaneous heparin injection: A randomized, single-blind, placebo-controlled trial
  150. The diagnostic performance of machine learning-based FFRCT for coronary artery disease: A meta-analysis
  151. Comparing biofeedback device vs diaphragmatic breathing for bloating relief: A randomized controlled trial
  152. Serum uric acid to albumin ratio and C-reactive protein as predictive biomarkers for chronic total occlusion and coronary collateral circulation quality
  153. Multiple organ scoring systems for predicting in-hospital mortality of sepsis patients in the intensive care unit
  154. Single-cell RNA sequencing data analysis of the inner ear in gentamicin-treated mice via intraperitoneal injection
  155. Suppression of cathepsin B attenuates myocardial injury via limiting cardiomyocyte apoptosis
  156. Influence of sevoflurane combined with propofol anesthesia on the anesthesia effect and adverse reactions in children with acute appendicitis
  157. Review Articles
  158. The effects of enhanced external counter-pulsation on post-acute sequelae of COVID-19: A narrative review
  159. Diabetes-related cognitive impairment: Mechanisms, symptoms, and treatments
  160. Microscopic changes and gross morphology of placenta in women affected by gestational diabetes mellitus in dietary treatment: A systematic review
  161. Review of mechanisms and frontier applications in IL-17A-induced hypertension
  162. Research progress on the correlation between islet amyloid peptides and type 2 diabetes mellitus
  163. The safety and efficacy of BCG combined with mitomycin C compared with BCG monotherapy in patients with non-muscle-invasive bladder cancer: A systematic review and meta-analysis
  164. The application of augmented reality in robotic general surgery: A mini-review
  165. The effect of Greek mountain tea extract and wheat germ extract on peripheral blood flow and eicosanoid metabolism in mammals
  166. Neurogasobiology of migraine: Carbon monoxide, hydrogen sulfide, and nitric oxide as emerging pathophysiological trinacrium relevant to nociception regulation
  167. Plant polyphenols, terpenes, and terpenoids in oral health
  168. Laboratory medicine between technological innovation, rights safeguarding, and patient safety: A bioethical perspective
  169. End-of-life in cancer patients: Medicolegal implications and ethical challenges in Europe
  170. The maternal factors during pregnancy for intrauterine growth retardation: An umbrella review
  171. Intra-abdominal hypertension/abdominal compartment syndrome of pediatric patients in critical care settings
  172. PI3K/Akt pathway and neuroinflammation in sepsis-associated encephalopathy
  173. Screening of Group B Streptococcus in pregnancy: A systematic review for the laboratory detection
  174. Giant borderline ovarian tumours – review of the literature
  175. Leveraging artificial intelligence for collaborative care planning: Innovations and impacts in shared decision-making – A systematic review
  176. Cholera epidemiology analysis through the experience of the 1973 Naples epidemic
  177. Risk factors of frailty/sarcopenia in community older adults: Meta-analysis
  178. Supplement strategies for infertility in overweight women: Evidence and legal insights
  179. Scurvy, a not obsolete disorder: Clinical report in eight young children and literature review
  180. A meta-analysis of the effects of DBS on cognitive function in patients with advanced PD
  181. Protective role of selenium in sepsis: Mechanisms and potential therapeutic strategies
  182. Strategies for hyperkalemia management in dialysis patients: A systematic review
  183. C-reactive protein-to-albumin ratio in peripheral artery disease
  184. Case Reports
  185. Delayed graft function after renal transplantation
  186. Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature
  187. Diverse electrophysiological demyelinating features in a late-onset glycogen storage disease type IIIa case
  188. Giant right atrial hemangioma presenting with ascites: A case report
  189. Laser excision of a large granular cell tumor of the vocal cord with subglottic extension: A case report
  190. EsoFLIP-assisted dilation for dysphagia in systemic sclerosis: Highlighting the role of multimodal esophageal evaluation
  191. Molecular hydrogen-rhodiola as an adjuvant therapy for ischemic stroke in internal carotid artery occlusion: A case report
  192. Coronary artery anomalies: A case of the “malignant” left coronary artery and its surgical management
  193. Rapid Communication
  194. Biological properties of valve materials using RGD and EC
  195. A single oral administration of flavanols enhances short-term memory in mice along with increased brain-derived neurotrophic factor
  196. Letter to the Editor
  197. Role of enhanced external counterpulsation in long COVID
  198. Expression of Concern
  199. Expression of concern “A ceRNA network mediated by LINC00475 in papillary thyroid carcinoma”
  200. Expression of concern “Notoginsenoside R1 alleviates spinal cord injury through the miR-301a/KLF7 axis to activate Wnt/β-catenin pathway”
  201. Expression of concern “circ_0020123 promotes cell proliferation and migration in lung adenocarcinoma via PDZD8”
  202. Corrigendum
  203. Corrigendum to “Empagliflozin improves aortic injury in obese mice by regulating fatty acid metabolism”
  204. Corrigendum to “Comparing the therapeutic efficacy of endoscopic minimally invasive surgery and traditional surgery for early-stage breast cancer: A meta-analysis”
  205. Corrigendum to “The progress of autoimmune hepatitis research and future challenges”
  206. Retraction
  207. Retraction of “miR-654-5p promotes gastric cancer progression via the GPRIN1/NF-κB pathway”
  208. Retraction of: “LncRNA CASC15 inhibition relieves renal fibrosis in diabetic nephropathy through downregulating SP-A by sponging to miR-424”
  209. Retraction of: “SCARA5 inhibits oral squamous cell carcinoma via inactivating the STAT3 and PI3K/AKT signaling pathways”
  210. Special Issue Advancements in oncology: bridging clinical and experimental research - Part II
  211. Unveiling novel biomarkers for platinum chemoresistance in ovarian cancer
  212. Lathyrol affects the expression of AR and PSA and inhibits the malignant behavior of RCC cells
  213. The era of increasing cancer survivorship: Trends in fertility preservation, medico-legal implications, and ethical challenges
  214. Bone scintigraphy and positron emission tomography in the early diagnosis of MRONJ
  215. Meta-analysis of clinical efficacy and safety of immunotherapy combined with chemotherapy in non-small cell lung cancer
  216. Special Issue Computational Intelligence Methodologies Meets Recurrent Cancers - Part IV
  217. Exploration of mRNA-modifying METTL3 oncogene as momentous prognostic biomarker responsible for colorectal cancer development
  218. Special Issue The evolving saga of RNAs from bench to bedside - Part III
  219. Interaction and verification of ferroptosis-related RNAs Rela and Stat3 in promoting sepsis-associated acute kidney injury
  220. The mRNA MOXD1: Link to oxidative stress and prognostic significance in gastric cancer
  221. Special Issue Exploring the biological mechanism of human diseases based on MultiOmics Technology - Part II
  222. Dynamic changes in lactate-related genes in microglia and their role in immune cell interactions after ischemic stroke
  223. A prognostic model correlated with fatty acid metabolism in Ewing’s sarcoma based on bioinformatics analysis
  224. Red cell distribution width predicts early kidney injury: A NHANES cross-sectional study
  225. Special Issue Diabetes mellitus: pathophysiology, complications & treatment
  226. Nutritional risk assessment and nutritional support in children with congenital diabetes during surgery
  227. Correlation of the differential expressions of RANK, RANKL, and OPG with obesity in the elderly population in Xinjiang
  228. A discussion on the application of fluorescence micro-optical sectioning tomography in the research of cognitive dysfunction in diabetes
  229. A review of brain research on T2DM-related cognitive dysfunction
  230. Metformin and estrogen modulation in LABC with T2DM: A 36-month randomized trial
  231. Special Issue Innovative Biomarker Discovery and Precision Medicine in Cancer Diagnostics
  232. CircASH1L-mediated tumor progression in triple-negative breast cancer: PI3K/AKT pathway mechanisms
Heruntergeladen am 10.12.2025 von https://www.degruyterbrill.com/document/doi/10.1515/med-2025-1165/html?lang=de
Button zum nach oben scrollen